



Atty. Dkt. No. 085747-0299

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Bradford Van Wagenen et al.
Title: HETEROPOLYCYCLIC COMPOUNDS AND THEIR
USE AS METABOTROPIC GLUTAMATE RECEPTOR
ANTAGONISTS
Appl. No.: 10/699,563
Filing Date: 11/03/2003
Examiner: Not yet assigned
Art Unit: Not yet assigned

INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR §1.56

Mail Stop PATENT APPLICATION
Commissioner for Patents
PO Box 1450
Alexandria, Virginia 22313-1450

Sir:

Applicants submit herewith on Form PTO/SB/08 a listing of the documents cited by or submitted to the U.S. PTO in parent application Serial No. 10/076,618, filed 02/19/2002. As provided in 37 CFR §1.98(d), copies of the documents are not being provided since they were previously submitted to the United States Patent & Trademark Office in the above-identified parent application.

The submission of any document herewith, which is not a statutory bar, is not intended as an admission that such document constitutes prior art against the claims of the present application or that such document is considered material to patentability as defined in 37 CFR §1.56(b). Applicants do not waive any rights to take any action which would be appropriate to antedate or otherwise remove as a competent reference any document which is determined to be a *prima facie* art reference against the claims of the present application.

TIMING OF THE DISCLOSURE

The listed documents are being submitted in compliance with 37 CFR §1.97(b), before the mailing date of the first Office Action on the merits.

RELEVANCE OF EACH DOCUMENT

Applicants respectfully request that any listed document be considered by the Examiner and be made of record in the present application and that an initialed copy of Form PTO/SB/08 be returned in accordance with MPEP §609.

The Commissioner is hereby authorized to charge any additional fees which may be required regarding this application under 37 CFR §§ 1.16-1.17, or credit any overpayment, to Deposit Account No. 19-0741. Should no proper payment be enclosed herewith, as by a check being in the wrong amount, unsigned, post-dated, otherwise improper or informal or even entirely missing, the Commissioner is authorized to charge the unpaid amount to Deposit Account No. 19-0741.

Respectfully submitted,

Date 19 April 2004

By Stephen A. Bent

FOLEY & LARDNER LLP

Customer Number: 22428

Telephone: (202) 672-5404

Facsimile: (202) 672-5399


Stephen A. Bent

Attorney for Applicant

Registration No. 29,768

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT Date Submitted: April 20, 2004 <i>(use as many sheets as necessary)</i>				Complete if Known	
		Application Number	10/699,563		
		Filing Date	11/03/2003		
		First Named Inventor	Bradford Van Wagenen		
		Group Art Unit	Not yet assigned		
		Examiner Name	Not yet assigned		
		Attorney Docket Number	085747-0299		
Sheet	1	of	2		



U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			
		3,647,809	A	Harsanyi et al.	3/7/1972	
		4,022,901	A	Narayanan et al.	5/10/1977	
		5,554,630		Teuber et al.	09/1996	
		3,647,809		Reiter et al.	03/1972	
		5,554,630		Teuber et al.	9/10/1996	
		4,003,909		Narayanan et al.	1/18/1977	

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Office ³	Number ⁴	Kind Code ⁵ (if known)				
			WO 01 12627 A		NPS Pharmaceuticals Inc.	2/22/2001		
X			WO 98 17652 A		Boehringer Ingelheim	4/30/1998		
X			WO 99 02497 A		Novartis Erfindungen	1/21/1999		
X			WO 97/0396706096		Rhone-Poulenc Rorer Limit	2/1997		
X			WO 94/22846		Pfizer Inc.	10/1994		
X			WO 94/22846	A1	Pfizer Inc.	10/13/1994		
X			WO 97/03967	A1	Rhonepoulenc Rorer Limited GB	02/06/1997		
X			WO 99/26927	A2	NPS Pharmaceuticals, Inc.	06/03/1999		
X			WO 98/57969		Hoechst Schering	12/1998		
X			DE 1 149 011		Farbwerke Hoechst Aktiengesellschaft	5/22/1963		

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.			T ⁶
X		M. OHKUBO et al., "Studies on Cerebral Protective Agents; VII. Synthesis of Novel 4-Acrylazole Derivatives with Anti-anoxic Activity", Chem. Pharmaceutical Bulletin; June 1995; pp. 947-954; Vol. 43; No. 6; Pharmaceutical Society of Japan.			
X		W. PEI et al., "Convenient Synthesis of 2-Alkyl (Aryl)-4, 5-diphenyloxazoles and 2-Alkyl (Aryl)-4 phenyloxazoles", Synthesis; September 1998, pp. 1298-1304; No. 9, China.			

X Did not receive

Examiner Signature	Date Considered	
--------------------	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, PO Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, PO Box 1450, Alexandria, Virginia 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT Date Submitted: April 20, 2004 <i>(use as many sheets as necessary)</i>		Application Number	10/699,563
		Filing Date	11/03/2003 APR 20 2004
		First Named Inventor	Bradford Van Wagenen
		Group Art Unit	Not yet assigned
		Examiner Name	Not yet assigned
Sheet 2 of 2	Attorney Docket Number	085747-0299	

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
X		C. MONTOLIU et al., "Activation of the Metabotropic Glutamate Receptor mGluR5 Prevents Glutamate Toxicity in Primary Cultures of Cerebellar Neurons", The Journal of Pharmacology and Experimental Therapeutics, May 2, 1997; pp. 643-647; Vol. 281; The American Society of Pharmacology and Experimental Therapeutics; USA.	
X		Ksasovitskij et al., Chemical Abstracts, Vol. 123, No. 22, Abstract 299726w,608h, page 477, 11/27/1995.	
X		Yurugi et al., Chemical Pharmaceutical Bulletin, Vol. 21, No. 8, pp., 1641-1650, 1973.	
X		William W. PAUDLER et al., "The Conversion of Imidazo[1,5-a]pyridines into 3-(2-Pyridyl)-1,2,4-oxadiazoles", Conversion of Imadazopyridines into Pyridyloxadiazoles, August 1967, pp. 2430-2433; Vol. 32; USA.	
X		T. Ross KELLY et al., "Total Synthesis of Dimethyl Sulfomycinamate", Tetrahedron Letters, 1995; pp. 5319-5322, Vol. 36, No. 30, Elsevier Science Ltd. UK.	
X		Wei HUANG et al., "A Novel Improved Procedure for the Synthesis of Oxazoles", Tetrahedron; 1996; pp. 10131-10136, Vol. 52, No. 30; Elsevier Science Ltd., UK.	
X		Mark A. MASSA et al., "Synthesis of Novel Substituted Pyridines as Inhibitors of Endothelin Converting Enzyme-1 (ECE-1); Bioorganic & Medicinal Chemistry Letters; 1998; pp. 2117-2122, Vol. 8, Elsevier Science Ltd., UK.	
X		Luciano VIO et al., "Note-low antihypertensive activity", Journal; 5807502; EN; 321; 1988; pgs. 713-717; Beilstein Instiut zur Foerderung der Chimischen Wissenschaften; Weinheim Germany.	
X		Helene PERRIER, et al., "Substituted Furans as Inhibitors of the PDE4 Enzyme"; Biorganic & Medicinal Chemistry Letters; 1999; pp. 323-326, Vol. 9, Elsevier Science Ltd. UK.	
		Edward E. GLOVER et al. "The Nitration of Imidazo[1,5-a] pyridines" J of the Chem. Soc., Perkins I, 1980, pp. 959-961.	
		Robert K. HOWE et al., "Nitrile Oxide Cycloaddition Routes to 2-(Isoxazolyl)-benzoates and 2-(1,2,4-Oxadiazol-3-yl)benzoates", J. of Het. Chem., Vol. 19, 1982, pp. 721-726.	

X Did not receive

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, PO Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, PO Box 1450, Alexandria, Virginia 22313-1450.